J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Joaquin Duato, CEO of J&J, stated: “Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting-edge medicines to treat patients in America and around the world.”

The announced additional investments kicked off with the groundbreaking of a new biologics manufacturing facility in Wilson, North Carolina. This facility will expand J&J's capacity to manufacture next-generation medicines for people living with cancer, immune-mediated, and neurological diseases and is expected to create over 500 new positions at the site.

In addition to the new site in Wilson, the J&J’s plans include three new manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses, as well as “significant” investments in R&D infrastructure and technology.

© Johnson & Johnson
© Johnson & Johnson

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation